TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Mon Dec 15

NL

Article

TMFBiologyFool published an article 5:15 PM

Twitter's Favorite Biotech and Pharma Stocks

Consensus? We don't need no stinking consensus!

Sun Dec 14

NL

Article

TMFBiologyFool published an article 1:04 AM

Better Big Pharma Spinoff: Zoetis Inc. or AbbVie Inc.?

Both AbbVie and Zoetis offer something for healthcare investors.

Sat Dec 13

NL

Article

TMFBiologyFool published an article 9:01 AM

Can These Top Dividend-Paying Stocks Soar in 2015?

There's more to top dividend-paying stocks than the yield.

Wed Dec 10

NL

Article

TMFBiologyFool published an article 4:34 PM

Is MannKind Corporation in Bed With Crooks? And Should Investors Care?

MannKind's marketing partner, Sanofi, may be in big trouble.

Thu Dec 4

NL

Article

TMFBiologyFool published an article 2:15 PM

Gilead Sciences, Inc. Beats Another Threat

A U.K. court knocks down Idenix Pharmaeuticals' rights to Gilead Sciences' Sovaldi.

Fri Nov 28

NL

Article

TMFBiologyFool published an article 12:22 AM

Dendreon's Alternate Reality

What if everything went perfectly right for the biotech?

Thu Nov 27

NL

Article

TMFBiologyFool published an article 3:46 PM

Bristol-Myers Squibb Co's Hep C Drug Denied; Gilead Sciences Inc. Smiling (for Now)

The FDA rejected daclatasvir, but Bristol-Myers Squibb still has plans for the hepatitis C drug.

Wed Nov 26

NL

Article

TMFBiologyFool published an article 8:15 AM

Will Insulin Pricing Be MannKind Corporation's Downfall?

MannKind marketing partner Sanofi had to discount its Lantus insulin to get insurers to cover the drug.

Thu Nov 20

NL

Article

TMFBiologyFool published an article 12:42 PM

Gilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a Year

Gilead's newly acquired priority review voucher is useful, but requires the biotech to give the FDA a 365-day warning that it's going to use the voucher.

Tue Nov 18

NL

Article

TMFBiologyFool published an article 4:00 PM

Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too

Thanks to Merck, Regeneron Pharmaceuticals and Esperion Therapeutics likely won't have to run outcomes studies on their cholesterol drugs.

Mon Nov 17

NL

Article

TMFBiologyFool published an article 1:50 PM

For This Obesity Drug, Europe Trumps the U.S.

Europe is key for Orexigen's Contrave. Shares jumped despite problems with the U.S. launch.

Mon Nov 10

NL

Article

TMFBiologyFool published an article 2:17 PM

Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much

Merck's new hepatitis C combination doesn't work all that well for short durations. Gilead Sciences' Harvoni is safe for now.

Fri Nov 7

Rule Breakers article.

TMFBiologyFool published an update. 4:58 PM

NL

Article

TMFBiologyFool published an article 2:29 PM

Isis Pharmaceuticals Inc. Strikes Out on Its Own

Isis Pharmaceuticals uses its third-quarter earnings call to announce a reorganization as it pushes into late-stage development on its own.

Rule Breakers article.

TMFBiologyFool published an update. 9:06 AM

Thu Nov 6

Rule Breakers article.

TMFBiologyFool published an update. 9:33 PM

NL

Article

TMFBiologyFool published an article 8:13 PM

Emergent BioSolutions Inc Busts Through Guidance. Sort of.

Emergent BioSolutions' upfront payment from its deal with MorphoSys caused a large increase in revenue in the third quarter.

NL

Article

TMFBiologyFool published an article 4:27 PM

5 Things Biogen Idec Inc's Management Wants You to Know

Biogen Idec's multiple sclerosis and hemophilia pipelines are progressing.

NL

Article

TMFBiologyFool published an article 3:17 PM

All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline

Isis has an approved drug, but earnings should be all about the pipeline of 32 drugs.

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 96.58
Player Rank 2570 out of 75071
Score 1326.29
Score Change Today -71.93
Accuracy 66.35%
Active Picks 73
Total Picks 213
Best Pick ISIS (+343.04)
Worst Pick INCY (-698.26)
Average Score per Pick 6.23
Charms Earned 10
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts